Key Highlights
- Michael Intrator, CEO, offloaded 77,939 shares for $5.77M at $74.05 per share, trimming his holdings by 1.34%
- On the identical trading day, March 31, CSO Brian Venturo dumped 65,005 shares worth $4.81M at $74.05
- The AI infrastructure firm secured an oversubscribed $8.5 billion GPU-collateralized credit facility
- Fourth-quarter sales reached $1.57B, marking a 110% annual increase, though losses per share of -$0.89 fell short of projections by $0.28
- Wall Street consensus leans toward “Moderate Buy” with analysts targeting $121.06 on average
Top executives at CoreWeave simultaneously dumped more than ten million dollars in company stock — yet the firm’s massive GPU-backed financing arrangement continues to fuel investor optimism.
CoreWeave, Inc. Class A Common Stock, CRWV
Michael Intrator, the company’s chief executive, disposed of 77,939 Class A common shares on March 31, executing the sale at $74.05 apiece for total proceeds of $5.77 million. This transaction decreased his ownership position by 1.34%, with his remaining stake of 5,728,900 shares valued at approximately $424 million based on recent trading levels.
Brian Venturo, serving as Chief Strategy Officer, executed a parallel sale on the identical date, offloading 65,005 shares at the matching $74.05 price point, generating $4.81 million in proceeds. Notably, Venturo simultaneously exercised options to obtain 126,752 shares through restricted stock unit conversions on that same trading day. Securities and Exchange Commission documents confirm both executives’ transactions.
The coordinated stock sales totaled more than $10.5 million across both company leaders in a single trading session.
Massive $8.5 Billion Credit Facility Dominates Headlines
The executive share disposals coincided with significantly larger corporate news: CoreWeave finalized an $8.5 billion delayed draw term loan arrangement — marking the company’s fourth such credit facility — backed by GPU assets and existing customer agreements. Demand for the financing exceeded available capacity, attracting participation from international banking institutions, investment management firms, and insurance sector investors.
Evercore ISI maintained its Outperform designation while setting a $120 valuation target after the announcement. Citizens JMP Securities preserved its Market Outperform stance with an $180 objective. Stifel retained a neutral position at $110, highlighting that the new facility reduces CoreWeave’s overall weighted average cost of capital.
The financing proceeds are designated for artificial intelligence infrastructure and data center build-outs, with market analysts widely identifying it as the primary driver behind the stock’s recent multi-percentage-point appreciation.
Revenue Acceleration Despite Bottom-Line Shortfall
CoreWeave’s latest quarterly performance presented contrasting narratives. Total revenue reached $1.57 billion, representing a 110% increase compared to the year-ago period — an exceptional expansion rate by industry standards.
However, profitability metrics disappointed. Earnings per share registered at -$0.89, falling short of analyst expectations of -$0.61 by $0.28. The organization maintains a debt-to-equity ratio of 4.46 alongside a negative net margin of 22.75%.
On the technological front, CoreWeave achieved top-tier performance in the MLPerf Inference v6.0 benchmark evaluations utilizing Nvidia GB200 and GB300 infrastructure. The company’s GB300 NVL72 configuration delivered double the benchmark scores achieved in the preceding MLPerf 5.1 testing cycle.
In separate developments, Barclays preserved an Equalweight assessment with a $90 valuation target, referencing reports of partnership modifications for a Texas-based data center initiative. Industry sources indicate Poolside is pursuing alternative collaborators following unsuccessful negotiations with CoreWeave.
Bank of America recently elevated CRWV from Neutral to Buy, establishing a $100 price objective. Goldman Sachs maintains a Neutral designation with an $86 target. Current Wall Street coverage includes nineteen Buy ratings, eleven Hold recommendations, and two Sell opinions.
The consensus analyst target price sits at $121.06 compared to the current trading price of $82.24, within a 52-week trading range spanning $33.51 to $187.00.
